{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:55:36Z","timestamp":1776142536769,"version":"3.50.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic prurigo nodularis (CPN) is a chronic, inflammatory, highly pruritic skin disease with a significant burden, but the epidemiological data available are still very limited. This study aimed to describe the sociodemographic and clinical profiles of real-world patients with CPN seen in dermatology consultations in Spain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ECOSPIN was a Spanish, observational, ecological, survey-based study with aggregated data obtained from the experience and routine clinical practice of 39 dermatologists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>According to the dermatologists, a mean of 29.1% of patients with CPN were aged 51\u201360\u202fyears, and the majority were women (61%). A mean of 97.9% experienced itching, with frequent comorbidities: atopic dermatitis (41.1%), hypertension (32.1%), anxiety (57.4%), and depression (43.6%). Dermatologists considered the etiology of CPN to be dermatological in a mean of 56.5% of cases. The primary treatments were topical corticosteroids and calcineurin inhibitors (91.2%). Among systemic therapies, dupilumab was the most used (51.8%) and was rated as the most effective. The most relevant treatment goal was rapid itch elimination or reduction, while managing comorbidities was important for minimizing healthcare resource utilization, based on the dermatologists\u2019 experience.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The study highlighted unmet needs and the high burden of CPN, emphasizing the need for multidisciplinary and individualized treatment approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1769149","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:21:29Z","timestamp":1776140489000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Experience in the management of real-world patients with chronic prurigo nodularis in a dermatology setting: results from the ECOSPIN Spanish survey-based study"],"prefix":"10.3389","volume":"13","author":[{"given":"Ignasi","family":"Figueras-Nart","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Universitari de Bellvitge, University of Barcelona","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Ortiz Castillo","sequence":"additional","affiliation":[{"name":"Sanofi S.A.","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"Serra Baldrich","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Sant Pau Hospital","place":["Barcelona, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","article-title":"Prurigo nodularis: epidemiology and clinical features","volume":"83","author":"Huang","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/medicines6040097","article-title":"Diagnostic workup and evaluation of patients with prurigo nodularis","volume":"6","author":"Kwon","year":"2019","journal-title":"Medicines (Basel)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jid.2024.06.1276","article-title":"Pathophysiology of prurigo nodularis: neuroimmune dysregulation and the role of type 2 inflammation","volume":"145","author":"Kwatra","year":"2025","journal-title":"J Invest Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1468-3083.2012.04481.x","article-title":"Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients","volume":"27","author":"Iking","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.jid.2019.07.697","article-title":"Real-world prevalence of prurigo nodularis and burden of associated diseases","volume":"140","author":"Huang","year":"2020","journal-title":"J Invest Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"318","DOI":"10.4103\/idoj.IDOJ_324_17","article-title":"The prevalence of psychiatric comorbidity in patients with prurigo nodularis","volume":"9","author":"Dhawan","year":"2018","journal-title":"Indian Dermatol Online J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/medicines6040098","article-title":"Racial and gender differences in the presentation of pruritus","volume":"6","author":"Whang","year":"2019","journal-title":"Medicines (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.jaad.2019.08.072","article-title":"Racial differences in dermatologic conditions associated with HIV: a cross-sectional study of 4679 patients in an urban tertiary care center","volume":"82","author":"Bender","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/jdv.15145","article-title":"The self-assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries","volume":"33","author":"Brenaut","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/medicines6030088","article-title":"Inpatient burden of prurigo nodularis in the United States","volume":"6","author":"Whang","year":"2019","journal-title":"Medicines (Basel)"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jaad.2020.04.182","article-title":"Prurigo nodularis: pathogenesis and management","volume":"83","author":"Williams","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/bjd\/ljae052","article-title":"Prurigo nodularis: new insights into pathogenesis and novel therapeutics","volume":"190","author":"Liao","year":"2024","journal-title":"Br J Dermatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","article-title":"Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials","volume":"29","author":"Yosipovitch","year":"2023","journal-title":"Nat Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12016-025-09054-1","article-title":"Effectiveness and safety of nemolizumab in patients with prurigo nodularis: a systematic review and meta-analysis of randomized controlled trials","volume":"68","author":"Raja","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref15","year":""},{"key":"ref16","year":""},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1111\/jdv.15107","article-title":"Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need","volume":"32","author":"Pereira","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/1346-8138.17400","article-title":"Current clinical practice of prurigo nodularis in Japan: a cross-sectional web-survey among dermatologists","volume":"52","author":"Murota","year":"2025","journal-title":"J Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e414","DOI":"10.1111\/1346-8138.16067","article-title":"2020 guidelines for the diagnosis and treatment of prurigo","volume":"48","author":"Satoh","year":"2021","journal-title":"J Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"T967","DOI":"10.1016\/j.ad.2024.09.011","article-title":"[Translated article] Consensus on the diagnostic algorithm for chronic nodular Prurigo","volume":"115","author":"de Ortiz Frutos","year":"2024","journal-title":"Actas Dermosifiliogr"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/12034754241227808","article-title":"Clinical characteristics and treatment outcomes of prurigo nodularis: a retrospective study","volume":"28","author":"Taghaddos","year":"2024","journal-title":"J Cutan Med Surg"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1301817","DOI":"10.3389\/fimmu.2023.1301817","article-title":"Molecular mechanisms of pruritus in prurigo nodularis","volume":"14","author":"Shao","year":"2023","journal-title":"Front Immunol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/jdv.14570","article-title":"European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo","volume":"32","author":"Pereira","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.bbi.2023.12.005","article-title":"Role of stress in skin diseases: a neuroendocrine-immune interaction view","volume":"116","author":"Zhang","year":"2024","journal-title":"Brain Behav Immun"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/jdv.19700","article-title":"Comorbidities, healthcare resource utilization & treatment pattern among patients with prurigo nodularis, compared to a benchmark in Germany: a real-world evidence claims data study","volume":"38","author":"Stander","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1093\/bjd\/ljae207","article-title":"Prevalence, incidence and treatment patterns of prurigo nodularis in England: a retrospective database analysis","volume":"191","author":"Bahloul","year":"2024","journal-title":"Br J Dermatol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"s12","DOI":"10.36849\/jdd.sf365502","article-title":"Patient journey and the burden of systemic comorbidities and sequalae in prurigo nodularis","volume":"22","author":"Kwatra","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s00403-025-03847-2","article-title":"Distinct comorbidity profiles in atopic versus non-atopic prurigo nodularis: a cross-sectional analysis","volume":"317","author":"Bao","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/ijd.17493","article-title":"Association between atopic dermatitis and prurigo nodularis: a systematic review and meta-analysis","volume":"64","author":"Li","year":"2025","journal-title":"Int J Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1022889","DOI":"10.3389\/fmed.2022.1022889","article-title":"Extracellular matrix and dermal nerve growth factor dysregulation in prurigo nodularis compared to atopic dermatitis","volume":"9","author":"Deng","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e908","DOI":"10.1111\/jdv.19013","article-title":"Impact of chronic prurigo nodularis on daily life and stigmatization","volume":"37","author":"Misery","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/j.jid.2023.12.003","article-title":"Comparing the efficacy of updated treatment choices for prurigo nodularis: a network meta-analysis","volume":"144","author":"Wang","year":"2024","journal-title":"J Invest Dermatol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/itx.0000000000000042","article-title":"IFSI-guideline on chronic prurigo including prurigo nodularis","volume":"5","author":"St\u00e4nder","year":"2020","journal-title":"ITCH"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/jcm13030878","article-title":"Dupilumab for treatment of prurigo nodularis: real-life effectiveness for up to 84 weeks","volume":"13","author":"Paganini","year":"2024","journal-title":"J Clin Med"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/j.jid.2023.12.021","article-title":"Single-cell RNA sequencing reveals dysregulated POSTN+WNT5A+ fibroblast subclusters in prurigo nodularis","volume":"144","author":"Patel","year":"2024","journal-title":"J Invest Dermatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2367615","DOI":"10.1080\/09546634.2024.2367615","article-title":"Estimating the healthcare burden of prurigo nodularis in England: a CPRD database study","volume":"35","author":"Bahloul","year":"2024","journal-title":"J Dermatol Treat"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s13555-025-01349-7","article-title":"Healthcare resource utilization and economic burden of prurigo nodularis in the United States","volume":"15","author":"Kwatra","year":"2025","journal-title":"Dermatol Ther Heidelb"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"475","DOI":"10.23736\/S2784-8671.24.07970-2","article-title":"Healthcare resource utilization and related cost among hospitalized patients with prurigo nodularis: a retrospective cohort study using Italian health claims data","volume":"159","author":"Bahloul","year":"2024","journal-title":"Ital J Dermatol Venerol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1769149\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T04:21:30Z","timestamp":1776140490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1769149\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":38,"alternative-id":["10.3389\/fmed.2026.1769149"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1769149","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"article-number":"1769149"}}